Global Sangers Sequencing Service Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

• In February 2023, The Tamil Nadu Forest Department in India launched a DNA sequencing facility (Sanger sequencing) under the Centre for Wildlife Forensics and established a wildlife histopathology laboratory under the Centre for Animal Care Sciences, enhancing wildlife research and conservation efforts.

• In June 2020, The FDA granted Illumina Emergency Use Authorization (EUA) for its COVIDSeq Test, designed to sequence the entire genome of the SARS-CoV-2 virus. The test processed over 3,000 samples using the NovaSeq 6000 technology, delivering results within 24 hours.

The Global Sanger Sequencing Service Market is segmented based on application, end-user, and geography. By application, the market is categorized into diagnostics, research, therapeutics, and others. The diagnostics segment holds a significant share due to the increasing incidence of genetic disorders and the necessity for precise genetic testing in clinical settings. In diagnostics, Sanger sequencing is extensively used for confirming mutations identified by next-generation sequencing (NGS), providing an essential validation step due to its high accuracy. Research applications are also substantial, driven by academic institutions and research organizations that utilize Sanger sequencing for various genetic studies and projects.

The market segmentation by end-user includes academic and government research institutes, pharmaceutical and biotechnology companies, hospitals and clinics, and others. Academic and government research institutes dominate this segment, attributed to the continuous need for genetic research and the ongoing projects that require detailed DNA sequencing. Pharmaceutical and biotechnology companies are also significant contributors, leveraging Sanger sequencing in drug discovery, development, and validation processes. Hospitals and clinics increasingly adopt these services for genetic testing to inform patient care and personalized treatment plans, highlighting the clinical importance of Sanger sequencing in modern healthcare.

Global Sangers Sequencing Service Segment Analysis

In this report, the Global Sangers Sequencing Service Market has been segmented by Application, End User, and Geography.

Global Sangers Sequencing Service Market, Segmentation by Application

The Global Sangers Sequencing Service Market has been segmented by Application into Diagnostics, Biomarkers & Cancer, Reproductive Health, Personalized Medicine, Forensics, and Others.

Biomarkers & cancer research constitute another significant application area, where Sanger sequencing aids in identifying genetic variations associated with cancer susceptibility, tumor progression, and treatment response. Its role extends to the validation of potential biomarkers and the characterization of tumor genomes, facilitating personalized oncology approaches and advancing cancer diagnostics and therapeutics.

Reproductive health stands as a vital application domain, leveraging Sanger sequencing for prenatal screening, preimplantation genetic testing, and diagnosing hereditary reproductive disorders. The technology's high accuracy and ability to detect single-nucleotide polymorphisms (SNPs) are invaluable in assessing genetic risks and ensuring the health of both mother and child.

Personalized medicine, propelled by the growing understanding of individual genetic makeup's influence on disease susceptibility and drug response, represents a burgeoning application area for Sanger sequencing. The technology enables comprehensive genetic profiling, guiding tailored treatment strategies and optimizing therapeutic outcomes for various medical conditions.

Forensics marks yet another critical application segment, where Sanger sequencing plays a crucial role in forensic DNA analysis, aiding in criminal investigations, identification of human remains, and resolving paternity disputes. Its reliability and ability to generate accurate DNA profiles from minute samples make it indispensable in legal and investigative proceedings.

Global Sangers Sequencing Service Market, Segmentation by End User

The Global Sangers Sequencing Service Market has been segmented by End User into Academic & Government Research Institutes, Pharmaceutical Companies, Biotechnology Companies, and Hospitals & Clinics.

Pharmaceutical companies represent another substantial end-user category, leveraging Sanger sequencing in drug discovery, development, and validation processes. From identifying potential drug targets and assessing drug safety to conducting pharmacogenomic studies for personalized medicine initiatives, these companies rely on accurate genetic data provided by Sanger sequencing to drive innovation and enhance therapeutic outcomes.

Biotechnology companies also form a significant portion of the market, harnessing Sanger sequencing for diverse applications spanning bioprocess optimization, agricultural biotechnology, and industrial enzyme production. These companies utilize sequencing services to characterize genetic resources, engineer microbial strains, and validate biotechnological products, thereby facilitating advancements across various sectors including healthcare, agriculture, and environmental biotechnology.

Hospitals and clinics constitute a crucial end-user segment, increasingly adopting Sanger sequencing for genetic diagnostics and personalized medicine initiatives. With the growing emphasis on precision medicine and the integration of genomic data into clinical practice, healthcare providers rely on sequencing services to diagnose genetic disorders, assess disease risk, and tailor treatment regimens to individual patient profiles. Sanger sequencing's accuracy and reliability make it a valuable tool in guiding clinical decision-making and improving patient outcomes across a wide spectrum of medical specialties.

Global Sangers Sequencing Service Market, Segmentation by Geography

In this report, the Global Sangers Sequencing Service Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Global Sangers Sequencing Service Market Share (%), by Geographical Region, 2024

North America emerged as the frontrunner, capturing a substantial portion of the market share. This dominance can be attributed to the region's advanced healthcare infrastructure, robust research and development activities, and significant investments in genetic testing and precision medicine initiatives. Moreover, the presence of key market players and academic institutions conducting cutting-edge genetic research further solidified North America's position as a leading market for Sanger sequencing services.

Europe held a considerable market share in the Global Sanger Sequencing Service Market. The region's strong research base, supportive regulatory environment, and increasing adoption of genomic technologies contributed to its market presence. European countries have been at the forefront of genetic research and personalized medicine initiatives, driving the demand for Sanger sequencing services across academic, clinical, and commercial sectors.

The Asia-Pacific region exhibited notable growth and market share in the Global Sanger Sequencing Service Market. Rapidly expanding healthcare infrastructure, growing awareness of genetic disorders, and rising investments in biomedical research fueled the demand for sequencing services in the region. Additionally, initiatives aimed at integrating genomics into healthcare systems and addressing the unmet medical needs further propelled market expansion in Asia-Pacific countries.

Latin America and the Middle East and Africa regions also contributed to the Global Sanger Sequencing Service Market, albeit to a lesser extent compared to the aforementioned regions. Factors such as improving healthcare access, increasing prevalence of genetic diseases, and rising investments in healthcare infrastructure and research capabilities drove market growth in these regions. However, challenges related to funding constraints, regulatory complexities, and limited access to advanced genomic technologies may have moderated the market share compared to other regions.

This report provides an in depth analysis of various factors that impact the dynamics of Global Sangers Sequencing Service Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunity Analysis

Drivers

• Technological Advancements
• Increasing Genomic Research
• Growing Prevalence

• Pharmaceutical Expansion - The pharmaceutical industry is experiencing significant growth, driven by advancements in biotechnology and an increasing emphasis on precision medicine. This expansion is a crucial driver for the Sanger sequencing service market. Pharmaceutical companies rely heavily on genomic data to identify genetic markers, understand disease mechanisms, and develop targeted therapies. Sanger sequencing, known for its high accuracy and reliability, remains a gold standard for validating next-generation sequencing (NGS) results and confirming genetic variations. As the pharmaceutical sector continues to innovate and expand its R&D capabilities, the demand for precise and reliable sequencing services such as those provided by Sanger sequencing is expected to rise.

  The pharmaceutical industry's push towards personalized medicine further underscores the importance of Sanger sequencing services. Personalized medicine aims to tailor treatments based on individual genetic profiles, requiring detailed and accurate genomic information. Sanger sequencing plays a vital role in this process, offering the necessary validation and verification of genetic data obtained through high-throughput methods. As pharmaceutical companies increasingly adopt personalized medicine approaches, the need for comprehensive and precise sequencing services will grow, thereby driving the market for Sanger sequencing. Additionally, collaborations between sequencing service providers and pharmaceutical companies can lead to the development of novel therapeutics, enhancing the overall impact on healthcare and patient outcomes.

Restraints

• High Costs
• Complex Interpretation
• Limited Availability

• Technical Limitations - Despite its widespread use and high accuracy, Sanger sequencing faces several technical limitations that can hinder its growth in the sequencing service market. One significant limitation is its relatively low throughput compared to next-generation sequencing (NGS) technologies. Sanger sequencing can only sequence a few hundred base pairs per run, making it less efficient for large-scale genomic projects that require the analysis of entire genomes or extensive regions of DNA. This lower throughput means that for extensive sequencing needs, Sanger sequencing is time-consuming and more labor-intensive, which can be a significant drawback in high-demand environments.

  Another technical limitation of Sanger sequencing is its higher cost per base sequenced compared to NGS methods. While Sanger sequencing provides high-quality data and is excellent for validating NGS results, its cost-efficiency diminishes as the scale of the project increases. This higher cost per base can make it less attractive for projects requiring extensive sequencing, where NGS offers a more cost-effective solution. Additionally, the need for high-quality DNA samples and the potential for errors in longer read sequences can add to the complexity and cost of Sanger sequencing projects, limiting its application in some research and clinical settings.

  The inherent limitations in detecting certain types of genetic variations pose challenges for Sanger sequencing. While it excels in identifying single nucleotide variations (SNVs) and small insertions or deletions, it is less effective in detecting larger structural variations, copy number variations (CNVs), and complex rearrangements within the genome. This limitation reduces its utility in comprehensive genomic studies where such variations are crucial for understanding genetic underpinnings of diseases. Consequently, while Sanger sequencing remains a valuable tool for specific applications, its technical constraints may limit its competitiveness against more advanced sequencing technologies that offer broader and more versatile genomic insights.

Opportunities

• Emerging Markets
• Personalized Medicine
• Strategic Partnerships

• Technological Integration - The integration of Sanger sequencing with other advanced technologies represents a significant opportunity for enhancing the capabilities and applications of sequencing services. By combining Sanger sequencing with next-generation sequencing (NGS), researchers can leverage the strengths of both methods: the high accuracy and reliability of Sanger sequencing and the high throughput and cost-efficiency of NGS. This hybrid approach allows for the initial broad analysis of genomes using NGS, followed by precise validation of specific genetic variations using Sanger sequencing. Such integration ensures comprehensive and accurate genetic analysis, making it particularly valuable in clinical diagnostics and personalized medicine.

  Incorporating Sanger sequencing with cutting-edge technologies like CRISPR gene editing can greatly expand its utility in genetic research and therapeutic development. CRISPR relies on precise identification and targeting of genetic sequences, a process where Sanger sequencing can play a critical role in validating the target sites and confirming the edits made. This synergy not only improves the accuracy of gene editing but also accelerates the development of gene therapies. By integrating these technologies, researchers and clinicians can achieve more precise genetic modifications and better understand the outcomes, thereby advancing the field of genetic engineering.

  The integration of Sanger sequencing with bioinformatics tools and artificial intelligence (AI) can significantly enhance data analysis and interpretation. Advanced bioinformatics platforms can manage and analyze the large volumes of data generated, providing deeper insights into genetic variations and their implications. AI algorithms can further refine this process by identifying patterns and predicting outcomes based on sequencing data. This technological integration can streamline workflows, reduce the time required for data interpretation, and increase the overall efficiency of sequencing services. As a result, service providers can offer more comprehensive and precise genomic solutions, catering to a broader range of research and clinical needs.

Key players in Global Sangers Sequencing Service Market include :

• GenHunter Corporation
• Genscript Biotech Corporation
• LGC Science Group Holdings Limited
• Microsynth AG
• Nucleics
• Quintara Biosciences
• SciGenom Labs
• Source BioScience Plc
• Thermo Fisher Scientific

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis